ArticlePloS one2020

Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.

Sheelagh Frame et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.